Form 4: Tarsus CCO Sells Shares for Tax Obligations

Tarsus Pharmaceuticals' Chief Commercial Officer, Aziz Mottiwala, sold 13,056 shares of common stock over three days to cover tax withholding obligations related to RSU vesting.

Summary

• Aziz Mottiwala, Chief Commercial Officer of Tarsus Pharmaceuticals, Inc. (TARS), reported sales of common stock.
• The sales occurred on March 17, 2026, March 18, 2026, and March 19, 2026.
• A total of 13,056 shares were sold across these three days.
• The shares were sold at prices ranging from $67.00 to $69.42 per share.
• The sales were non-discretionary, mandated by the Issuer's election to require a 'sell to cover' transaction to satisfy tax withholding obligations from the vesting and settlement of Restricted Stock Units (RSUs).
• Following these transactions, Aziz Mottiwala beneficially owns 61,480 shares of Tarsus Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale of shares by the Chief Commercial Officer was non-discretionary and solely for covering tax withholding obligations related to RSU vesting, rather than a discretionary decision to reduce exposure.

Management Comments

• The sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units.
• The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions, where executives sell shares to satisfy tax obligations arising from equity awards, are a common and routine occurrence in the pharmaceutical industry and across public companies. These transactions are typically pre-planned under Rule 10b5-1 and are generally not indicative of an insider's discretionary view on the company's future prospects or stock performance.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine, non-discretionary sales for tax purposes and do not signal a change in management's confidence or company fundamentals.

Key Dates

Recommendation

The reported transactions are 'sell to cover' sales, which are non-discretionary and solely for tax withholding purposes related to RSU vesting. This type of insider transaction is routine and does not reflect a change in the reporting person's discretionary investment decision or the company's fundamental outlook. Therefore, it provides no new information that would warrant a change in investment recommendation, suggesting a 'hold' position based on this filing alone.

Keywords

Tarsus Pharmaceuticals, TARS, Form 4, Insider Transaction, Stock Sale, RSU, Tax Withholding, Aziz Mottiwala